Shimon Slavin

This inventor holds 24 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Hadasit Medical Research Services and Development Ltd., Hadasit Medical Research Services and Development Company, Ben-Gurion University of the Negev Research and Development Authority. Active years: 1995-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shimon Slavin. Retrieved from https://idiyas.com/inventor/shimon-slavin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24 (Patent Applications = 2)

% Patents Active = 83.3

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 2.5

ph-index = 9

Forward Citations = 256(Granted Patents)

Location History:

Tel Aviv, IL (2015 - 2016)
Jerusalem, IL (1995 - 2017)

Company Filing History:

8 out of 182

Hadasit Medical Research Services and Development Ltd.

patents

5 out of 31

Hadasit Medical Research Services and Development Company

patents

4 out of 365

Ben-Gurion University of the Negev Research and Development Authority

patents

4. 4 out of 916

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

5. 3 out of 4

Agricultural Research Organization Ministry of Agriculture

patents

6. 2 out of 2,533

Baxter International Inc.

patents

7. 1 out of 1

Agricultural Organization Ministry of Agriculture State of Israel

patent

8. 1 out of 1

Agricultural Research Org. Ministry of Agriculture (Gov.)

patent

9. 1 out of 1

Hadasitmedical Research Serv. & Devel. Ltd.

13. 2 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2017

Loading Chart...

Areas of Expertise:

Telomerase Activating Compounds

Tri-Aryl Compounds

Sphingolipids

Cannabidiol

Trifunctional Antibodies

Hematopoietic Disorders

Non-Myeloablative Treatment

Quinazolinone Derivatives

Allogeneic Cell Therapy

Osteogenic Growth Polypeptides

Anti-Fibrotic Compositions

Quinoline Carboxamide

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9670139 - Telomerase activating compounds and methods of use thereof (2017-06-06),

2. 9663448 - Tri-aryl compounds and compositions comprising the same (2017-05-30),

3. 9340488 - Synthetic analogs of sphingolipids (2016-05-17),

4. 8962891 - Synthetic analogs of sphingolipids (2015-02-24),

5. 8609736 - Telomerase activating compounds and methods of use thereof (2013-12-17),

6. 8604245 - Tri-aryl compounds and compositions comprising the same (2013-12-10),

7. 8071641 - Treating or preventing diabetes with cannabidiol (2011-12-06),

8. 8066989 - Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy (2011-11-29),

9. 7347999 - Methods of treatment of hematopoietic disorders (2008-03-25),

10. 6544787 - Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation (2003-04-08),

11. 6447767 - Non-myeloablative tolerogenic treatment (2002-09-10),

12. 6428782 - Non-myeloablative tolerogenic treatment (2002-08-06),

13. 6159488 - Intracoronary stents containing quinazolinone derivatives (2000-12-12),

14. 6143292 - Allogeneic cell therapy for cancer following allogeneic stem cell (2000-11-07),

15. 6090814 - Quinazolinone-containing pharmaceutical compositions for prevention of (2000-07-18),

Title: Shimon Slavin: Innovator in Telomerase Research

Introduction

Shimon Slavin, based in Jerusalem, IL, is a prolific inventor with a remarkable portfolio of 24 patents. His work primarily focuses on innovations in the field of medical research, particularly concerning telomerase and its implications for treating various diseases and disorders.

Latest Patents

Among his latest inventions are "Telomerase activating compounds and methods of use thereof," which addresses the activation of telomerase using specific compounds to treat related conditions. Another significant contribution is the "Tri-aryl compounds and compositions comprising the same," which presents a novel class of tri-aryl compounds along with processes for their preparation. These patents exemplify his commitment to advancing medical science.

Career Highlights

Shimon has worked with Hadasit Medical Research Services and Development Ltd. as well as Hadasit Medical Research Services and Development Company. Through his efforts in these organizations, he has made significant contributions to medical research, focusing on the innovative applications of his patented compounds.

Collaborations

Throughout his career, Shimon Slavin has collaborated with prominent figures in the field, including Arnon Nagler and Mark Pines. These collaborations have undoubtedly enhanced his research capabilities and contributed to his successful inventions.

Conclusion

In summary, Shimon Slavin stands out as an influential inventor whose work in telomerase research has the potential to impact medical treatment significantly. His extensive patent portfolio and collaborations demonstrate his dedication to innovation and improving healthcare solutions.

Profile summary based on public USPTO records.